1.Hematoxylin's cytocidal and apoptosis-inducing effects on human urinary bladder cancer cell-T24
Liansheng REN ; Hung ZHANG ; Xihua BAI ; Xuebing HAN ; Zhenguo MI
Cancer Research and Clinic 2008;20(12):799-801
Objective To observe hematoxylin's cytocidal and apoptosis-inducing effects on human urinary cancer cell-T24,and its cytocidal mechanism to the target cell.Methods Target cells were incubated in the medium 1640 for 24h,which contained hematoxylin in dosage of zero(blank),12.5,25,50,100,200μg/ml,respectively;under inverted microscopy to observe target cells'morphologic change,and then harvest them;by trypan blue tmpochrome method to determine hematoxylin's cytocidal activity to the target cells;by flow cytomelry to detect the effects of hematoxylin in its different levels on target cells'apoptosis.Results The control group(without hematoxylin)showed their target cells in a fusiform adherent growth,plump,close-arranged,and with a good transparence.With the addition and increment of hematoxylin,target cells turned round,not adherent,pyknotic,with a bad transparence,as well as chromatin condensation,the cells clumped.Cell death rate of control group was(2.63±0.29)%,with the increased dosage of hematoxylin the cell death rate of test groups was(10.00±4.82)%,(21.88±3.42)%,(76.41±4.82)%,(92.27±6.54)%,and(96.34±8.70)%respectively.Flow cytometry showed cell apoptosis rate in control group was 0.47%(occurred spontaneously),but hematoxylin in dose of 50μg/ml made the apoptosis rate increased markedly,to 43.1 8%,dead cell rate 48.47%,and survival cell rate 8.35%.With the increased hematoxylin dose,cell apoptosis rate decreased gradually,while dead cell rate increased.Conclusion Hematoxylin can inhibit the target cell by two routes:to induce apoptose or kill it.In a lower dose it is able to induce target cell to apeptose;hematoxylin in a dose over 100μg/ml can directly kill the target cell.Making this trial for checking the cell's morphologic changes benefits determining the optimal dosage level and optimal acting duration for the apoptosis induction.
2.Comparison on hematoxylin, cisplatin, hydroxycamptothecine and ather medicine in celiac chemotherapy for mice hepatoma (HepA) model and their inhibitory effect
Liansheng REN ; Hong ZHANG ; Xihua BAI ; Lei FAN ; Yongming YANG ; Na ZHAO
Cancer Research and Clinic 2009;21(2):84-86
Objective To compare the inhibitory effects to mice ascitic hepatoma (HepA) among hematoxylin,mitomycin,cisplatin,hydroxycamptothecine and other medicine in celiac chemotherapeutic route,probing into the credibility of hematoxylin in celiac chemotherapy.Methods Mice ascitic HepA model was set up by celiac inoculation of HepA strains.24 h after the inoculation,intraperitoneal administration was done,then raising the mice as routine.Their body weights were measured regularly,living quality observed,mean survival times compared among these groups.Having repeated the above experiment three tines,T/C values obtained in the three experiments were compared one another.Results The awerage survival time of mice of control group (inoculated but no medicine used) was 15.99-16.33 d; that of hematoxylin group was 36.35-39.81 d; that of mitomycin gro.up was 35.77-40.06 d; that of hydroxycamptothecine survived 20.79-38.47 d; and that of cisplatin group was 32.98-41.89 d.A comprehensive comparison showed that mitomycin group and hematoxylin group had better effects.Conclusion Hematoxylin in celiac chemotherapy has an outstanding effect to the mice's transplanted HepA,no significant difference with mitomycin.However,hydroxycamptothecine and cisplatin are not good enough.
3.Immunological effect of tumor cell vaccines to hepatoma A (HepA) treated by different adjuvant of Haematoxylin
Fang YANG ; Cong ZHANG ; Xihua BAI ; Na ZHAO ; Lei YAN ; Yongming YANG ; Liansheng REN
Cancer Research and Clinic 2009;21(1):11-13
Objective To observe the immunological effect of tumor cell vaccines to mouse hepatoma A(HepA) treated by Haematoxylin. Methods HepA cell was treated by 0.1% Haematoxylin and made into three vaccines: HepA vaccine with complete Freund' s adjuvant, HepA vaccine with incomplete Freund' s adjuvant; and HepA vaccine without any adjuvants. Five times of immunization were given the grouped mice with the above three vaccines, then active HepA cells (1×105 for each mouse) were inoculated by intraperitoneal injection to attack them; reckoning the mean survival time (MST) of the grouped mice, comparing the immunoprotective action of the three vaccines to the tmnor-bearing mice. Those mice only receiving normal saline (equal volume to the vaccine) were as a control group. Results MST of control group was (23.30±1.24) day; MST of mice receiving H22 vaccine with complete adjuvant was (43.90±15.20) day (P<0.02); MST of mice receiving H22 vaccine with incomplete adjuvant was (39.60±13.77) day (P<0.05); and MST of mice receiving HepA vaccine without any adjuvant was (38.40±12.54) day (P<0.05); As compared with the control group, the three treated groups showed a life-lengthening rate (LLR) 88.41%, 69.96 % and 64.81% respectively. Conclusion The vaccines treated by Haematoxylin give a marked immunoprotective action to those tumor-bearing mice. The HepA vaccine' s immunological effect is increased by the Freund' s adjuvant (complete or incomplete).
4.Clinical Research Guidelines for Treatment of Osteoporosis with New Uyghur Medicine (Draft)
Abudukelimu ABUDUWAILI ; Aibai SILAFU ; Pingshan WANG ; Maitinuer YUSUFU ; Wusiman MUHAMAITI ; Hong ZHANG ; Liansheng BAI ; Jinfeng LI ; Zhijian LI ; Abuduaini ABUDUJILILI ; Gongshu LI ; Binglin LIU ; Xiaojing PEI ; Bei ZHOU
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(10):1-4
In this study, retrospective multi-center study on medical records of Uyghur medicine diagnosis and treatment program of osteoporosis was done and demographic, diagnostic, therapeutic, efficacy evaluation and nursing data and other information were collected. The main and secondary disease manifestations of osteoporosis were analyzed inductively. Osteoporosis was divided into 2 types in Uyghur medicine field, which were abnormal Savda type and abnormal Balgham type. Uighur medicine syndrome type standards of osteoporosis were established. Treatment efficacy was evaluated according to bone pain, bone density, life quality, and improvement of clinical symptoms and Uyghur medical symptoms. On this basis, in accordance with the technical requirements of the national drug review, the study developed clinical research guidelines for the treatment of osteoporosis with new Uyghur medicine (draft).
5.Clinical Research Guidelines for Treatment of Acne Vulgaris with New Uyghur Medicine ;(Draft)
Abudukelimu ABUDUWAILI ; Aibai SILAFU ; Pingshan WANG ; Wufuer TUERXUN ; Maitinuer YUSUFU ; Wusiman MUHAMAITI ; Hong ZHANG ; Aximu TUERHONG ; Liansheng BAI ; Jinfeng LI ; Maihemute GUHAER ; Abuduaini ABUDUJILILI ; Zhijian LI ; Gongshu LI ; Binglin LIU ; Xiaojing PEI ; Bei ZHOU
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(2):1-4
In this article, retrospective multi-center study on medical records of Uyghur Medicine diagnosis and treatment program of acne vulgaris was done and demographic, diagnostic, therapeutic, efficacy evaluation and nursing data and other information were collated and analyzed. The main and secondary disease manifestations of acne vulgaris were analyzed inductively and acne vulgaris was divided into 3 types in Uyghur Medicine field, which are blood-type acne vulgaris, yellow bile-type acne vulgaris, and astringent mucus-type acne vulgaris. Uyghur Medicine syndrome type standards of acne vulgaris were established. At the same time, through evaluating skin integrity and morphology of lesions as well as changes in patients’ symptoms and quality of life and observing changes in patients’ internal environment respectively before and after treatment, disease and syndrome clinical criteria of acne vulgaris were established. On this basis, in accordance with the technical requirements of the national medicine review, this study developed clinical research guidelines for the treatment of acne vulgaris with new Uyghur Medicine.
6.Clinical Research Guidelines for Treatment of Hyperlipidemia with New Uyghur Medicine (Draft)
Abudukelimu ABUDUWAILI ; Aibai SILAFU ; Pingshan WANG ; Wufuer ASIYA ; Maitinuer YUSUFU ; Wusiman MUHAMAITI ; Maimaiti MAINISHA ; Aximu TUERHONG ; Hong ZHANG ; Liansheng BAI ; Jinfeng LI ; Zhijian LI ; Abuduaini ABUDUJILILI ; Gongshu LI ; Binglin LIU ; Xiaojing PEI ; Bei ZHOU
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(6):1-5
Based on medical ethics, retrospective multi-center study on medical records of Uyghur Medicine diagnosis and treatment program of hyperlipidemia was done and demographic, diagnostic, therapeutic, efficacy evaluation, nursing data and other information were collated. The main and secondary disease manifestations of hyperlipidemia were analyzed inductively and hyperlipidemia were divided into 4 types in Uyghur Medicine field, which were surplus and sticky Kan type, Chuchumal Balgham type, Gaisiman Balgham type, and Koygan Savda type. Therefore, Uighur Medicine syndrome type standards of hyperlipidemia were established. Treatment efficacy was evaluated with the combination of laboratory observation parameters and main and secondary disease manifestations. On this basis, in accordance with the technical requirements of the national medicine review, this study developed clinical research guidelines for the treatment of hyperlipidemia with new Uyghur Medicine (draft).
7.Clinical Research Guidelines for Treatment of Common Cold with New Uyghur Medicine (Draft)
Abudukelimu ABUDUWAILI ; Aibai SILAFU ; Pingshan WANG ; Maitinuer YUSUFU ; Wusiman MUHAMAITI ; Maimaiti MAINISHA ; Aximu TUERHONG ; Hong ZHANG ; Liansheng BAI ; Jinfeng LI ; Zhijian LI ; Abuduaini ABUDUJILILI ; Gongshu LI ; Binglin LIU ; Xiaojing PEI ; Bei ZHOU
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(5):1-4
In this study, retrospective multi-center study on medical records of Uyghur Medicine diagnosis and treatment program of common cold was done and demographic, diagnostic, therapeutic, efficacy evaluation and nursing data and other information were collected, sorted out and analyzed to determine the diagnostic cretiria of Uygur Medicine syndrome factors. Syndrome differentiation standard with the syndrome factors of the enrties of main syndromes and sub-syndromes and symptomatic diagnosis chart was established. Combined with the symptoms of common cold, the efficacy evaluation standards were established. On this basis, in accordance with the technical requirements of the national new medicine review, the study developed clinical research guidelines for the treatment of common cold with new Uyghur Medicine (draft).
8.Clinical Research Guidelines for Treatment of Shingles with New Uyghur Medicine (Draft)
Abudukelimu ABUDUWAILI ; Aibai SILAFU ; Pingshan WANG ; Wufuer TUERXUN ; Maitinuer YUSUFU ; Wusiman MUHAMAITI ; Hong ZHANG ; Aximu TUERHONG ; Saimaiti REFUHATI ; Liansheng BAI ; Jinfeng LI ; Abuduaini ABUDUJILILI ; Zhijian LI ; Gongshu LI ; Binglin LIU ; Xiaojing PEI ; Bei ZHOU
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(1):1-4
This research conducted retrospective multi-center study on medical records of Uyghur Medicine diagnosis and treatment program of shingles, and collected information about demography, diagnostics, and therapeutics, efficacy evaluation and nursing to conclude and analyze the main syndromes and sub-disease performance. Shingles was divided into 3 types in Uyghur Medicine field: abnormal blood type shingles, abnormal bile liquid type shingles, and abnormal black choledochal typeshingles. Uighur Medicine syndrome type standards of shingles were established. Rash suspended time, rash dry scab time, the pain start to ease time interval, time completely pain, pain bounce rate, the incidence of postherpetic neuralgia, and PHN recovery time were evaluated. Disease and syndrome clinical criteria of shingles were established by evaluating Uygur Medical symptoms improvement, improvement of patients’ life quality and the changes in patients’ internal environment. On this basis, in accordance with the technical requirements of the national medicine review, the research developed clinical research guidelines for the treatment of shingles with new Uyghur Medicine (draft).
9.Progress of autophagy in treatment of chronic myelogenous leukemia
Jun BAI ; Bo HE ; Mouzhen HUANG ; Liansheng ZHANG
Journal of Leukemia & Lymphoma 2018;27(7):441-444
Autophagy plays an important role in the occurrence,progression and treatment of cancer,neurodegenerative,autoimmune and inflammatory diseases.Recent years,autophagy has become a new hot spot in tumor area.Chronic myelogenous leukemia (CML) is a common hematopoietic malignancy;while autophagy is involved in its development,as well as targeting drug tyrosine kinase inhibitor resistance mechanisms,regulating autophagy provide a new direction for the treatment of CML.The intensive study of the relation between cell autophagy and cancer will help to overcome cancer.This article offers an up-to-date comprehensive review of autophagy and CML.
10.Immuno-effect of plasmacytoid dendritic cells on bacteria infection induced spontaneous remission of leukemia.
Lijuan LI ; Liansheng ZHANG ; Ye CHAI ; Pengyun ZENG ; Chongyang WU ; Lingling YUE ; Jun BAI ; Zhengdong HAO ; Wanli HU ; Huiling CHEN ; Xiaojia GUO
Chinese Journal of Hematology 2014;35(10):880-884
OBJECTIVETo explore the immuno-effect of plasmacytoid dendritic cells (pDC) on bacteria infection induced spontaneous remission (SR) of leukemia.
METHODSBoth pDC and myeloid dendritic cells (mDC) were isolated and purified from leukemic patient with SR and healthy donor by combination of immunomagnetic beads and flow cytometry. pDC were cultured in RPMI1640 medium and stimulated with different bacteria. The T cells proliferation was detected by MTT, and cytokine production by ELISA kits.
RESULTSThe human bacterial pathogen Staphylococcus aureus and Pseudomonas aeruginosa stimulation for 48 h resulted in the maturation of pDC with production of high quantity of IFN-α at (15.34 ± 2.91) ng/ml and (10.38 ± 1.41) ng/ml, respectively, comparing with that of negative group at (1.36 ± 0.13) ng/ml (P<0.01). Activated pDC could promote the differentiation of naive CD4⁺ T cells to Th1 cells with secretion of IFN-γ at (2.16 ± 0.37) ng/ml and (2.73 ± 1.11) ng/ml, respectively, comparing with that of positive control at (2.55 ± 0.23) ng/ml (P > 0.05). Activated pDC showed higher T cell stimulatory capacities [proliferation index (PI) was 4.36 and 4.05, respectively] than that of non-activated pDC (PI was 1.23 and 0.13, respectively) (P < 0.01).
CONCLUSIONStaphylococcus aureus and Pseudomonas aeruginosa activated pDC may play a key role in SR of leukemia following severe infections.
CD4-Positive T-Lymphocytes ; Dendritic Cells ; immunology ; Flow Cytometry ; Humans ; Interferon-alpha ; Leukemia ; diagnosis ; immunology ; Lymphocyte Activation ; Pseudomonas aeruginosa ; immunology ; Remission, Spontaneous ; Staphylococcus aureus ; immunology